Mode
Text Size
Log in / Sign up
N/A N=749 Randomized Double-blind Treatment

Optimize Low Back Pain

Low Back Pain · Chronic Pain

Enrolled (actual)
749
Serious AEs
3.2%
Results posted
Mar 2026
Primary outcome: Primary: Change in Oswestry Disability Index From Baseline to 10 Weeks — -8.8; -6.1 Units on a scale — p=0.02

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Physical Therapy (Behavioral); Cognitive Behavioral Therapy (Behavioral); Mindfulness (Behavioral); Phase I Treatment (Behavioral); Phase II Switching (Behavioral)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University of Utah
Primary completion
Oct 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Oswestry Disability Index From Baseline to 10 Weeks
-8.8; -6.1 0.02 sig
PRIMARY
Change in Oswestry Disability Index From 10-weeks to 52 Weeks
-5.4; -4.9 0.76
PRIMARY
Change in Numeric Pain Intensity Rating From Baseline to 10 Weeks
-1.2; -0.84 0.03 sig
PRIMARY
Change in Numeric Pain Intensity Rating From 10-weeks to 52 Weeks
-0.53; -0.48 0.80
SECONDARY
Health-related Quality of Life
SECONDARY
Change in Pain Interference From Baseline to 10 Weeks
-4.0; -2.2 0.002 sig
SECONDARY
Change in Fatigue From Baseline to !0 Weeks
-1.2; 0.25 0.03 sig
SECONDARY
Change in Sleep Disturbance From Baseline to 10 Weeks
-2.1; -0.60 0.007 sig
SECONDARY
Change in Anxiety From Baseline to 10 Weeks
0.43; 2.5 0.002 sig
SECONDARY
Change in Depression From Baseline to 10 Weeks
1.3; 2.0 0.32
SECONDARY
Change in Social Role Participation From Baseline to 10 Weeks
1.9; 0.50 0.01 sig
SECONDARY
Health Care Utilization of Advanced Imaging for Back Pain Over 10 Weeks
27; 30 0.35
SECONDARY
Opioid Utilization at 10-week Assessment
32; 35 0.16
SECONDARY
Treatment Side Effects
46; 24 0.032 sig
SECONDARY
Treatment Responder
73; 38 0.001 sig
SECONDARY
Health Care Utilization of Injections for Back Pain Over 10 Weeks
12; 31 0.003 sig
SECONDARY
Health Care Utilization of Radiographs for Back Pain Over 10 Weeks
14; 16 0.50

Summary

The objective of this study is to improve health care for patients with chronic LBP and increase the likelihood that patients obtain outcomes that matter most to them. The investigators will accomplish our goal using a sequential multiple randomization (SMART) design comparing the effectiveness of Phase 1 (PT v. CBT) treatments for patients with chronic LBP; and among patient non-responsive to Phase I treatment, compare the effectiveness of Phase II treatments (switching to PT or CBT v. mindfulness). Effectiveness will be based on patient-centered outcomes. Sub-aims will compare main effects of Phase 1 and 2 treatment options and the sequencing effects of different treatment combinations.

Eligibility Criteria

Inclusion Criteria

  • Age 18 - 64 years at the time of enrollment.
  • Meets NIH Task Force definition of chronic LBP based on two questions: 1) How long has LBP has been an ongoing problem for you? and 2) How often has LBP been an ongoing problem for you over the past 6 months? A response of greater than 3 months to question 1, and "at least half the days in the past 6 months" to question 2 is required to satisfy the NIH definition of chronic LBP.
  • Healthcare visit for LBP in the past 90 days.
  • At least moderate levels of pain and disability requiring ODI score >24 and pain intensity rating > 4.
  • Has access to two-way video technology, such as smartphone, iPad/tablet, or laptop with webcam for telehealth visits.

Exclusion Criteria

  • Evidence of serious pathology as a cause of LBP including neoplasm, inflammatory disease (e.g., ankylosing spondylitis), vertebral osteomyelitis, etc.
  • Evidence of a specific spinal pathology as the cause of LBP including spine fracture, spinal stenosis, radiculopathy, etc.
  • Knowingly pregnant
  • Has received physical therapy for LBP; or CBT or mindfulness for any reason with a provider in prior 90 days
  • Currently receiving substance use disorder treatment
  • Any lumbar spine surgery in the past year.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03859713). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search